Clinical trial
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
NCT00108758 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT00108758 |
|---|---|
| Title | Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia |
| Official title | Exploratory, Multi-centre, Randomised, Double-blind, Uncontrolled Trial Evaluating the Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Secondary Bleeding Prophylaxis in Congenital Haemophilia A or B Patients With Inhibitors |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors |
| Intervention type | Drug |
| Interventions | activated recombinant human factor VII |
| Enrollment | 23 |
| Start date | Mar 1, 2004 |
| Primary completion | Nov 1, 2005 |
| Completion | Nov 1, 2005 |
| First posted | Apr 19, 2005 |
| Last update posted | Jan 12, 2017 |
| Countries | Argentina, Brazil, Bulgaria, France, Philippines, Poland, Romania, Russia, South Africa, Spain, Turkey (Türkiye), United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: